We studied the prevalence of prior CMV infection in 295 consecutive homosexual and bisexual men presenting to the department of genitourinary medicine in Sheffield. Serum was obtained at their presentation and tested for CMV antibodies by three methods: haemagglutination (Cetus Corporation of California), latex agglutination (CMV Scan, Becton & Dickinson), and an enzyme linked immunosorbent assay (ELISA) (CMV Antigen, Institute Virion). Patients were deemed to be seropositive iftwo or more tests gave positive results.
Two hundred and thirty two (78-6%) men were seropositive, the mean (SD) age of seropositive men was 31-9 (8 6) and mean number of sexual partners in the preceding three months was 2 5 (3 2). These values did not differ appreciably from those found in seronegative men. We found significant correlations between seropositivity and a history of gonorrhoea (p=0 05), hepatitis B (p=005), and genital warts (p=0 05), butno correlation with previous syphilis or nonspecific genital infection (table) .
This prevalence of CMV infection in our clinic population of provincial homosexual men was significantly less than that reported by Mindel and Sutherland, who found 93% of their 152 patients to be seropositive (X2=16; p<0 001). This lower prevalence may relate to differences between the populations in terms of ethnic background (only seven (2A4%) ofour patients were non-white) or sexual behaviour.
CMV infection may cause immune suppression and has been implicated in the acquired immune deficiency syndrome as a cofactor in the development of Kaposi's sarcoma3 and major opportunistic infections. Geographical differences in the prevalence of 
